Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Gina Klee, Patrick Terheyden, Jonas K. Kurzhals, Victoria Hagelstein, Detlef Zillikens, Ewan A. Langan, Andreas Recke
Publikováno v:
Melanoma Research. 31:464-471
Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined w
Autor:
Reinhard Dummer, Valerie C Amann, Anita Giobbie-Hurder, Simone M. Goldinger, Donald P. Lawrence, Lisa Zimmer, Joanna Mangana, Elisabeth Livingstone, Joshua Z. Drago, Tianqi Chen, Alfred Zippelius, Marco Siano, Ryan J. Sullivan
Publikováno v:
Melanoma Research. 29:65-69
BRAF and MEK kinase inhibitors can be highly effective in treating BRAF-mutant melanomas, but their safety and activity in patients with active/symptomatic brain metastases are unclear. We sought to shed light on this open clinical question. We condu
Publikováno v:
Melanoma research. 29(1)
Immune checkpoint inhibitor (IO) induced colitis is primarily managed with corticosteroids. Most patients have a rapid resolution of symptoms and do not require additional immunosuppressants. Many patients, however, require prolonged corticosteroid c
Autor:
Alexander Guminski, Dariush Douraghi-Zadeh, Alexander M. Menzies, Paolo A. Ascierto, Serigne Lo, Timmothy Harrington, Malinda Itchins, Meredith Oatley, Antonio M. Grimaldi, Richard Maher
Publikováno v:
Melanoma research. 27(3)
Metastatic uveal melanoma is a rare malignancy with a poor prognosis. To date, systemic therapy has been ineffective; however, there are few data on the benefits of anti-CTLA4 or anti-PD-1 antibodies in sequence with liver-directed therapy. A retrosp
Autor:
Giuseppe Guerriero, Andrea De Gaetano, Silvio Lippa, Andrea Paradisi, Luigi Rusciani, Antonio Rusciani, Alessia Mammone, Ilaria Proietti
Publikováno v:
Melanoma Research. 17:177-183
Early surgical intervention remains the most successful therapy for melanoma. Despite better outcomes observed in soft tissue and lymph node metastases, the results of pharmacological therapies are still disappointing. Currently, there is no standard
Autor:
O Rixe, C. Borel, D. Paraiso, A. Benhammouda, T. Petit, E. Antoine, J. P. Bizzari, G. Auclerc, C. Soubrane, M. Weil, B. Giroux, P. Banzet, D. Khayat
Publikováno v:
Melanoma Research. 5:419-424
Fotemustine and dacarbazine constitute the most active single chemotherapeutic agents in the treatment of melanoma. In this phase II study we evaluated the activity and toxicity of a combination of fotemustine, dacarbazine and vindesine as a means of
Autor:
Kevin B. Kim, Mandy S Harting
Publikováno v:
Melanoma research. 14(6)
Patients with advanced vulvovaginal mucosal melanoma generally have a dismal prognosis, and no effective systemic therapy for the disease has been reported. The objective of this retrospective clinical study was to assess the clinical benefit of bioc
Publikováno v:
Melanoma research. 13(2)
The prognosis of patients with metastatic melanoma remains poor and there is a need to develop new regimens with low toxicity. We investigated a novel outpatient regimen combining oral and intravenous chemotherapy with daily subcutaneous bleomycin. T
Autor:
Adriano Paccagnella, Gianluigi Cetto, Adolfo Favaretto, Rolando Nortilli, M. Medici, Savina Maria Luciana Aversa, Luigi Corti, Silvio Monfardini, V. Chiarion Sileni
Publikováno v:
Melanoma research. 11(2)
This randomized phase II trial was performed to define the activity and toxicity of the combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin (DDP) and tamoxifen (DBDT regimen) versus DTIC alone in patients with metastatic melanoma. Sixty p
Publikováno v:
Melanoma research. 10(4)
In a series of 92 patients with malignant melanoma, clinical stage III or IV, both 5-S-cysteinyldopa (5SCD) and 6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MI2C) were measured in urine during chemotherapy. A total of 434 urine specimens were anal